サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487587

経眼ドラッグデリバリー技術市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Ocular Drug Delivery Technology Market (Technology: Topical, Ocular Insert, Iontophoresis, Intraocular Implant, In Situ Gel & Punctal Plug, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 214 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.55円
経眼ドラッグデリバリー技術市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月11日
発行: Transparency Market Research
ページ情報: 英文 214 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経眼ドラッグデリバリー技術市場- 調査範囲

TMRの調査レポート「世界の経眼ドラッグデリバリー技術市場」は、2024年から2034年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2024年を基準年、2034年を予測年として、2018年から2034年までの世界の経眼ドラッグデリバリー技術市場の収益を提供しています。また、2024年から2034年までの世界の経眼ドラッグデリバリー技術市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、経眼ドラッグデリバリー技術市場を理解しました。

市場スナップショット
2023年の市場規模 163億米ドル
2034年の市場価値 302億米ドル
CAGR 5.7%

本レポートでは、世界の経眼ドラッグデリバリー技術市場の競合情勢を掘り下げています。世界の経眼ドラッグデリバリー技術市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の経眼ドラッグデリバリー技術市場のプレイヤーの属性です。

目次

第1章 序文

第2章 調査前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場の分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：技術別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：技術別, 2020-2034
    • 局所用
    • 眼用インサート
      • 消臭性
      • 非消耗性
    • イオントフォレーシス
    • 眼内インプラント
      • 生分解性
      • 非生分解性
    • In Situジェル・眼穿孔プラグ
    • その他
  • 市場魅力度：技術別

第7章 世界市場分析・予測：製剤タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製剤タイプ別、2020年～2034年
    • 溶液
    • 懸濁液
    • エマルジョン
    • リポソーム・ナノ粒子
    • 軟膏
  • 市場魅力度：製剤タイプ別

第8章 世界市場分析・予測：疾患タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患タイプ別、2020-2034年
    • 緑内障
    • 黄斑変性症
    • 糖尿病網膜症
    • 白内障
    • 糖尿病黄斑浮腫
    • ドライアイ症候群
    • その他
  • 市場魅力度：疾患タイプ別

第9章 世界市場分析・予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 病院
    • 外来手術センター
    • 眼科クリニック
    • 在宅医療
  • 市場魅力度：エンドユーザー別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別, 2020-2034
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と展望

第15章 中東・アフリカ市場の分析と予測

第16章 競合情勢

  • 市場競合マトリックス（企業階層別、企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Ocular Therapeutix, Inc.
    • Alimera Sciences Inc.
    • Allergan（an AbbVie company）
    • Bausch Health Companies Inc.
    • EyeGate Pharmaceuticals, Inc.
    • Envisia Therapeutics Inc.
    • Clearside Biomedical, Inc.
    • Graybug Vision, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Taiwan Liposome Company, Ltd.
図表

List of Tables

  • Table 01: Global Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 02: Global Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 03: Global Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 05: Global Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 08: North America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 09: North America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 10: North America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 13: Europe Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 14: Europe Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 15: Europe Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 18: Asia Pacific Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 19: Asia Pacific Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 20: Asia Pacific Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 23: Latin America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 24: Latin America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 25: Latin America Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Technology, 2020-2034
  • Table 28: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Formulation Type, 2020-2034
  • Table 29: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by Disease Type, 2020-2034
  • Table 30: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Ocular Drug Delivery Technology Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Ocular Drug Delivery Technology Market Revenue (US$ Mn), by Technology, 2023
  • Figure 03: Global Ocular Drug Delivery Technology Market Value Share, by Technology, 2023
  • Figure 04: Global Ocular Drug Delivery Technology Market Revenue (US$ Mn), by Formulation Type, 2023
  • Figure 05: Global Ocular Drug Delivery Technology Market Value Share, by Formulation Type, 2023
  • Figure 06: Global Ocular Drug Delivery Technology Market Revenue (US$ Mn), by Disease Type, 2023
  • Figure 07: Global Ocular Drug Delivery Technology Market Value Share, by Disease Type, 2023
  • Figure 08: Global Ocular Drug Delivery Technology Market Revenue (US$ Mn), by End-user, 2023
  • Figure 09: Global Ocular Drug Delivery Technology Market Value Share, by End-user, 2023
  • Figure 10: Global Ocular Drug Delivery Technology Market Value Share, by Region, 2023
  • Figure 11: Global Ocular Drug Delivery Technology Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 13: Global Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 14: Global Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 15: Global Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 16: Global Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 17: Global Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 18: Global Ocular Drug Delivery Technology Market Revenue (US$ Mn), by End-user, 2023
  • Figure 19: Global Ocular Drug Delivery Technology Market Value Share, by End-user, 2023
  • Figure 20: Global Ocular Drug Delivery Technology Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Ocular Drug Delivery Technology Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Ocular Drug Delivery Technology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Ocular Drug Delivery Technology Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 26: North America Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 27: North America Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 28: North America Ocular Drug Delivery Technology Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 30: North America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 31: North America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 32: North America Ocular Drug Delivery Technology Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Ocular Drug Delivery Technology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Ocular Drug Delivery Technology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Ocular Drug Delivery Technology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 37: Europe Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 38: Europe Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 39: Europe Ocular Drug Delivery Technology Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 41: Europe Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 42: Europe Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 43: Europe Ocular Drug Delivery Technology Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Ocular Drug Delivery Technology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Ocular Drug Delivery Technology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Ocular Drug Delivery Technology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 48: Asia Pacific Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 49: Asia Pacific Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 50: Asia Pacific Ocular Drug Delivery Technology Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 52: Asia Pacific Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 53: Asia Pacific Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 54: Asia Pacific Ocular Drug Delivery Technology Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Ocular Drug Delivery Technology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Ocular Drug Delivery Technology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 59: Latin America Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 60: Latin America Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 61: Latin America Ocular Drug Delivery Technology Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 63: Latin America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 64: Latin America Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 65: Latin America Ocular Drug Delivery Technology Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Ocular Drug Delivery Technology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Ocular Drug Delivery Technology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Ocular Drug Delivery Technology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Ocular Drug Delivery Technology Market Value Share Analysis, by Technology, 2023 and 2034
  • Figure 70: Middle East & Africa Ocular Drug Delivery Technology Market Value Share Analysis, by Formulation Type, 2023 and 2034
  • Figure 71: Middle East & Africa Ocular Drug Delivery Technology Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 72: Middle East & Africa Ocular Drug Delivery Technology Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Ocular Drug Delivery Technology Market Attractiveness Analysis, by Technology, 2024-2034
  • Figure 74: Middle East & Africa Ocular Drug Delivery Technology Market Attractiveness Analysis, by Formulation Type, 2024-2034
  • Figure 75: Middle East & Africa Ocular Drug Delivery Technology Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 76: Middle East & Africa Ocular Drug Delivery Technology Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL2869

Ocular Drug Delivery Technology Market - Scope of Report

TMR's report on the global ocular drug delivery technology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global ocular drug delivery technology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ocular drug delivery technology market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ocular drug delivery technology market.

Market Snapshot
Market Value in 2023US$ 16.3 Bn
Market Value in 2034US$ 30.2 Bn
CAGR5.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ocular drug delivery technology market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global ocular drug delivery technology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ocular drug delivery technology market.

The report delves into the competitive landscape of the global ocular drug delivery technology market. Key players operating in the global ocular drug delivery technology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global ocular drug delivery technology market profiled in this report.

Key Questions Answered in Global ocular drug delivery technology Market Report:

  • What is the sales/revenue generated by ocular drug delivery technology across all regions during the forecast period?
  • What are the opportunities in the global ocular drug delivery technology market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Ocular Drug Delivery Technology Market - Research Objectives and Research Approach

The comprehensive report on the global ocular drug delivery technology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global ocular drug delivery technology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ocular drug delivery technology market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ocular Drug Delivery Technology Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Ocular Drug Delivery Technology Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Technology

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Technology, 2020-2034
    • 6.3.1. Topical
    • 6.3.2. Ocular Insert
      • 6.3.2.1. Erodible
      • 6.3.2.2. Non-erodible
    • 6.3.3. Iontophoresis
    • 6.3.4. Intraocular Implant
      • 6.3.4.1. Biodegradable
      • 6.3.4.2. Non-biodegradable
    • 6.3.5. In Situ Gel & Punctal Plug
    • 6.3.6. Others
  • 6.4. Market Attractiveness, by Technology

7. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Formulation Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Formulation Type, 2020-2034
    • 7.3.1. Solution
    • 7.3.2. Suspension
    • 7.3.3. Emulsion
    • 7.3.4. Liposome & Nanoparticle
    • 7.3.5. Ointment
  • 7.4. Market Attractiveness, by Formulation Type

8. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Disease Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Disease Type, 2020-2034
    • 8.3.1. Glaucoma
    • 8.3.2. Macular Degeneration
    • 8.3.3. Diabetic Retinopathy
    • 8.3.4. Cataract
    • 8.3.5. Diabetic Macular Edema
    • 8.3.6. Dry Eye Syndrome
    • 8.3.7. Others
  • 8.4. Market Attractiveness, by Disease Type

9. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Ambulatory Surgical Centers
    • 9.3.3. Ophthalmic Clinics
    • 9.3.4. Homecare Settings
  • 9.4. Market Attractiveness, by End-user

10. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Ocular Drug Delivery Technology Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Technology, 2020-2034
    • 11.2.1. Topical
    • 11.2.2. Ocular Insert
      • 11.2.2.1. Erodible
      • 11.2.2.2. Non-erodible
    • 11.2.3. Iontophoresis
    • 11.2.4. Intraocular Implant
      • 11.2.4.1. Biodegradable
      • 11.2.4.2. Non-biodegradable
    • 11.2.5. In Situ Gel & Punctal Plug
    • 11.2.6. Others
  • 11.3. Market Attractiveness, by Technology
  • 11.4. Market Value Forecast, by Formulation Type, 2020-2034
    • 11.4.1. Solution
    • 11.4.2. Suspension
    • 11.4.3. Emulsion
    • 11.4.4. Liposome & Nanoparticle
    • 11.4.5. Ointment
  • 11.5. Market Attractiveness, by Formulation Type
  • 11.6. Market Value Forecast, by Disease Type, 2020-2034
    • 11.6.1. Glaucoma
    • 11.6.2. Macular Degeneration
    • 11.6.3. Diabetic Retinopathy
    • 11.6.4. Cataract
    • 11.6.5. Diabetic Macular Edema
    • 11.6.6. Dry Eye Syndrome
    • 11.6.7. Others
  • 11.7. Market Attractiveness, by Disease Type
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Ambulatory Surgical Centers
    • 11.8.3. Ophthalmic Clinics
    • 11.8.4. Homecare Settings
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Technology
    • 11.11.2. By Formulation Type
    • 11.11.3. By Disease Type
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Ocular Drug Delivery Technology Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Technology, 2020-2034
    • 12.2.1. Topical
    • 12.2.2. Ocular Insert
      • 12.2.2.1. Erodible
      • 12.2.2.2. Non-erodible
    • 12.2.3. Iontophoresis
    • 12.2.4. Intraocular Implant
      • 12.2.4.1. Biodegradable
      • 12.2.4.2. Non-biodegradable
    • 12.2.5. In Situ Gel & Punctal Plug
    • 12.2.6. Others
  • 12.3. Market Attractiveness, by Technology
  • 12.4. Market Value Forecast, by Formulation Type, 2020-2034
    • 12.4.1. Solution
    • 12.4.2. Suspension
    • 12.4.3. Emulsion
    • 12.4.4. Liposome & Nanoparticle
    • 12.4.5. Ointment
  • 12.5. Market Attractiveness, by Formulation Type
  • 12.6. Market Value Forecast, by Disease Type, 2020-2034
    • 12.6.1. Glaucoma
    • 12.6.2. Macular Degeneration
    • 12.6.3. Diabetic Retinopathy
    • 12.6.4. Cataract
    • 12.6.5. Diabetic Macular Edema
    • 12.6.6. Dry Eye Syndrome
    • 12.6.7. Others
  • 12.7. Market Attractiveness, by Disease Type
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospitals
    • 12.8.2. Ambulatory Surgical Centers
    • 12.8.3. Ophthalmic Clinics
    • 12.8.4. Homecare Settings
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Technology
    • 12.11.2. By Formulation Type
    • 12.11.3. By Disease Type
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Ocular Drug Delivery Technology Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Technology, 2020-2034
    • 13.2.1. Topical
    • 13.2.2. Ocular Insert
      • 13.2.2.1. Erodible
      • 13.2.2.2. Non-erodible
    • 13.2.3. Iontophoresis
    • 13.2.4. Intraocular Implant
      • 13.2.4.1. Biodegradable
      • 13.2.4.2. Non-biodegradable
    • 13.2.5. In Situ Gel & Punctal Plug
    • 13.2.6. Others
  • 13.3. Market Attractiveness, by Technology
  • 13.4. Market Value Forecast, by Formulation Type, 2020-2034
    • 13.4.1. Solution
    • 13.4.2. Suspension
    • 13.4.3. Emulsion
    • 13.4.4. Liposome & Nanoparticle
    • 13.4.5. Ointment
  • 13.5. Market Attractiveness, by Formulation Type
  • 13.6. Market Value Forecast, by Disease Type, 2020-2034
    • 13.6.1. Glaucoma
    • 13.6.2. Macular Degeneration
    • 13.6.3. Diabetic Retinopathy
    • 13.6.4. Cataract
    • 13.6.5. Diabetic Macular Edema
    • 13.6.6. Dry Eye Syndrome
    • 13.6.7. Others
  • 13.7. Market Attractiveness, by Disease Type
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Ambulatory Surgical Centers
    • 13.8.3. Ophthalmic Clinics
    • 13.8.4. Homecare Settings
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Technology
    • 13.11.2. By Formulation Type
    • 13.11.3. By Disease Type
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Ocular Drug Delivery Technology Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Technology, 2020-2034
    • 14.2.1. Topical
    • 14.2.2. Ocular Insert
      • 14.2.2.1. Erodible
      • 14.2.2.2. Non-erodible
    • 14.2.3. Iontophoresis
    • 14.2.4. Intraocular Implant
      • 14.2.4.1. Biodegradable
      • 14.2.4.2. Non-biodegradable
    • 14.2.5. In Situ Gel & Punctal Plug
    • 14.2.6. Others
  • 14.3. Market Attractiveness, by Technology
  • 14.4. Market Value Forecast, by Formulation Type, 2020-2034
    • 14.4.1. Solution
    • 14.4.2. Suspension
    • 14.4.3. Emulsion
    • 14.4.4. Liposome & Nanoparticle
    • 14.4.5. Ointment
  • 14.5. Market Attractiveness, by Formulation Type
  • 14.6. Market Value Forecast, by Disease Type, 2020-2034
    • 14.6.1. Glaucoma
    • 14.6.2. Macular Degeneration
    • 14.6.3. Diabetic Retinopathy
    • 14.6.4. Cataract
    • 14.6.5. Diabetic Macular Edema
    • 14.6.6. Dry Eye Syndrome
    • 14.6.7. Others
  • 14.7. Market Attractiveness, by Disease Type
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Ambulatory Surgical Centers
    • 14.8.3. Ophthalmic Clinics
    • 14.8.4. Homecare Settings
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Technology
    • 14.11.2. By Formulation Type
    • 14.11.3. By Disease Type
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Ocular Drug Delivery Technology Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Technology, 2020-2034
    • 15.2.1. Topical
    • 15.2.2. Ocular Insert
      • 15.2.2.1. Erodible
      • 15.2.2.2. Non-erodible
    • 15.2.3. Iontophoresis
    • 15.2.4. Intraocular Implant
      • 15.2.4.1. Biodegradable
      • 15.2.4.2. Non-biodegradable
    • 15.2.5. In Situ Gel & Punctal Plug
    • 15.2.6. Others
  • 15.3. Market Attractiveness, by Technology
  • 15.4. Market Value Forecast, by Formulation Type, 2020-2034
    • 15.4.1. Solution
    • 15.4.2. Suspension
    • 15.4.3. Emulsion
    • 15.4.4. Liposome & Nanoparticle
    • 15.4.5. Ointment
  • 15.5. Market Attractiveness, by Formulation Type
  • 15.6. Market Value Forecast, by Disease Type, 2020-2034
    • 15.6.1. Glaucoma
    • 15.6.2. Macular Degeneration
    • 15.6.3. Diabetic Retinopathy
    • 15.6.4. Cataract
    • 15.6.5. Diabetic Macular Edema
    • 15.6.6. Dry Eye Syndrome
    • 15.6.7. Others
  • 15.7. Market Attractiveness, by Disease Type
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospitals
    • 15.8.2. Ambulatory Surgical Centers
    • 15.8.3. Ophthalmic Clinics
    • 15.8.4. Homecare Settings
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Technology
    • 15.11.2. By Formulation Type
    • 15.11.3. By Disease Type
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Ocular Therapeutix, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Alimera Sciences Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Allergan (an AbbVie company)
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Bausch Health Companies Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. EyeGate Pharmaceuticals, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Envisia Therapeutics Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Clearside Biomedical, Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Graybug Vision, Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Santen Pharmaceutical Co., Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Taiwan Liposome Company, Ltd.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview